Newsroom

LONDON--(BUSINESS WIRE)--  09-June-2026 Issue: Newday Funding Master Issuer Plc 2025-1 Class F 144A XS3031615621 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-May-2026 Date To: 15-June-2026 Record Date: 12-June-2026 Value Date: 15-June-2026 Benchmark Rate: 3.73552717% Margin: 4.3% Total Rate: 8.03552717% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Total Amount Due: GBP 0....

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Perfect Moment Ltd. (the “Company”) — ticker symbol PMNT — from NYSE American. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the “Company Guide”) as the Company was unable to demonstrate that it had...

LONDON--(BUSINESS WIRE)--  09-June-2026 Issue: Newday Funding Master Issuer Plc SERIES 2024-2 Class E RegS XS2834468832 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-May-2026 Date To: 15-June-2026 Record Date: 12-June-2026 Value Date: 15-June-2026 Benchmark Rate: 3.73553% Margin: 3.9% Total Rate: 7.63553% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Total Amount Due: GBP 1...

LONDON--(BUSINESS WIRE)--  09-June-2026 Issue: Newday Funding Master Issuer Plc 2025-1 Class F REGS XS3031616272 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-May-2026 Date To: 15-June-2026 Record Date: 12-June-2026 Value Date: 15-June-2026 Benchmark Rate: 3.73553% Margin: 4.3% Total Rate: 8.03553% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Total Amount Due: GBP 23,886.4...

LONDON--(BUSINESS WIRE)--  10-June-2026 Issue: Mitsubishi HC Capital UK Plc Series 949 XS3181450753 Care Amendment Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 16-March-2026 Date To: 15-June-2026 Record Date: 12-June-2026 Value Date: 15-June-2026 Benchmark Rate: 3.63759% Margin: 0.5% Total Rate: 4.13759% Floor: 0% Number of Days: 91 Day Count: Actual / 360 Interest Frequency: Quarterly Total Amount Du...

SAN MATEO, Calif.--(BUSINESS WIRE)--Maxima, the leading agentic AI platform for Enterprise accounting, today announced it has been named one of the 2026 Best Places to Work in the Bay Area by the San Francisco Business Times and the Silicon Valley Business Journal. "When we started Maxima, we knew we wanted to attract some of the best talent in the Bay Area, and we believe we've done exactly that," said Yogi Goel, Co-founder and CEO of Maxima. "We're a team driven by a larger mission to give ac...

SAN FRANCISCO--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Farallon Capital Management, L.L.C. (on behalf of funds managed jointly with Farallon Capital Europe LLP and Farallon Partners, L.L.C.) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming...

SHERMAN OAKS, Calif. & THE WOODLANDS, Texas--(BUSINESS WIRE)--BIG3 HoldCo LLC (“BIG3”), recognized as the world’s premier professional 3-on-3 basketball league, founded by O’Shea Jackson (Ice Cube) and Jeff Kwatinetz, and Graf Global Corp. (NYSE American: GRAF) ("GRAF"), a publicly traded special purpose acquisition company, jointly announced that they have entered into a definitive agreement for a business combination. When the transaction closes, the publicly traded company will be named Big3...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa oncológica global, anunció hoy la presentación de nuevos resultados de fase 3 en pacientes de 80 años o más con leucemia linfocítica crónica o linfoma linfocítico de células pequeñas (LLC/LLP). Los datos muestran que BRUKINSA mantiene resultados clínicos favorables tras casi 6,5 años de seguimiento, lo que reafirma su eficacia en esta población. BRUKINSA es el único inhibidor de BTK que ha...

LONDON--(BUSINESS WIRE)--  Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For...